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Purpose: Coffee and tea are very common nonalcoholic beverages. However, their intake, 
particularly that of coffee, has been suggested to increase intraocular pressure (IOP) in patients 
with open angle glaucoma/ocular hypertension. The causative agent has been suggested to be 
their caffeine content. The objective of this study was to determine if this represents a direct 
caffeine effect. This study was therefore done using pure caffeine applied directly to the eyes.
Methods: The study was conducted with five human volunteers with open angle glaucoma/
ocular hypertension. IOP was measured using a Perkins applanation tonometer. Eye drops 
of 1% caffeine were prepared in-home. Following the initial (basal) measurement of the IOP, 
50 µL of the eye drop preparation was instilled in the eye at 0-, 4-, and 6-hour intervals. IOPs 
were measured 30 minutes after each instillation. A second study was also undertaken follow-
ing the first. In this study, the same patients instilled the eye drops three times per day for 1 week 
at home and then returned to the clinic on day 7. They were then again treated with caffeine 
eye drops as above and IOPs measured.
Results: In the 1-day study, the mean basal IOP was 23.6 ± 2.80 mmHg. Thirty minutes after 
instillation of the drops as described, the pressures were 23.2 ± 1.93, 22.2 ± 1.99, and 22.6 ± 2.31. 
The basal reading was taken at 10 am and another reading was then taken at 10.30 am. Additional 
eye drops were instilled at 2 and  8 pm and readings taken 30 minutes after each instillation. In 
the 1 week study, the basal value was 22.6 ± 2.32. After instillation of the drops as above the 
values were 23 ± 2.16, 22.4 ± 2.27, and 23 ± 1.94.
Conclusion: Administration of caffeine into the eyes of patients did not have any effect on IOP 
and it remained relatively unchanged. This was true in the 1-day study as well as in the 1-week 
study. A cumulative effect was not visible. The results therefore demonstrate that caffeine has 
no significant effect on IOP in patients with glaucoma. Any effects reported in coffee drinkers 
may therefore be related to other constituents in coffee, known to be generated pyrolytically from 
endogenous constituents of coffee beans by roasting at relatively high temperature, combined 
with the osmotic effects imposed by adequate fluid intake, known to be common in glaucoma 
patients.
Keywords: caffeine, open angle glaucoma, intraocular pressure, ocular hypertension
Introduction
Caffeine (1,3,7-trimethylxanthine) is a significant ingredient in several common 
  beverages such as coffee, tea, and colas, as well as in various other food items such as 
cakes and candies. A regular cup of coffee (236 mL) contains 135–150 mg of caffeine.1 
On average, daily consumption from normal coffee drinking alone is over 200 mg per 
day, although amounts up to 400 mg per day have been reported from certain European 
countries.2,3 Such amounts of caffeine are known to exert several   physiological effects Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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such as stimulation of the central nervous system (CNS), 
cardiac excitation, relaxation of bronchial and vascular 
smooth muscles, and promotion of diuresis and intestinal 
motility.4,5
Although most of these caffeine effects are ultimately 
related to its effect of increasing levels of cytosolic calcium 
ions, the specific mechanisms involved and the magnitude 
of the physiological effects differ from one tissue to another. 
Stimulation of the CNS, for example, is attributed to a com-
petitive blockade of the adenosine receptors situated at the 
presynaptic nerve terminals.6–9 This is due to the structural 
similarities between adenosine and caffeine, both purine 
derivatives. Since the binding of adenosine to its receptor 
regulates the voltage-gated calcium channels, blockade of 
these receptors results in an increased influx of calcium 
from the extracellular milieu into the cell cytosol, causing 
an increase in the synaptic release of neurotransmitters, 
including acetylcholine, norepinephrine, dopamine, and 
others involved in neural transduction and cardiovascular 
stimulation.9–11
The stimulation of cardiac muscle contraction by caf-
feine12–14 has been attributed to its binding with ryanodine-
sensitive Ca++ channels in the sarcoplasmic reticulum15–18 and 
consequent release of the sequestered Ca++ into the cytosol. In 
turn, the increased cytosolic Ca++ stimulates muscle contrac-
tion via interaction with the actomyosin complex.
The vasodilatory effect of Ca++ is exerted through 
Ca++-dependent activation of nitric oxide synthase, result-
ing in the elevation of nitric oxide and cyclic guanosine 
monophosphate levels.19 Caffeine also has several metabolic 
effects20–23 exerted through an inhibition of cyclic adenosine 
monophosphate (c-AMP) phosphodiesterase24 leading to an 
enhancement of c-AMP levels in the cells.
In summary, most of the neural and extraneural effects 
of caffeine are exerted through its action on intracellular 
levels of free calcium and inhibition of phosphodiesterase. 
However, several recent biochemical studies demonstrate 
that it is also an effective scavenger of reactive oxygen spe-
cies, including the hydroxyl radical OH•.25–33 The product 
of such a reaction is the formation of the 8-oxo derivative 
of caffeine, known as N-trimethyl urate. However, direct 
generation of OH• in vivo is a rarity. Usually it takes place by 
the interaction of hydrogen peroxide and superoxide, which 
by themselves are potent oxidants, detoxified normally by 
superoxide dismutase, catalase, and glutathione peroxidase. 
The generation of OH• is hence greatly minimized in most 
tissues, except in the cases of the eye and the skin where 
its generation remains consistent via several photochemical 
reactions.29
Studies on the pathophysiological effects of caffeine in 
the eye are still very limited. However, coffee drinking has 
been suggested to cause a transient elevation of intraocular 
pressure (IOP) in patients with glaucoma. The magnitude of 
such pressure elevation ranges from 1 to 2 mmHg, an hour 
after drinking coffee.34–37 The significance of this relatively 
small elevation in the face of a normal IOP of 14–22 mmHg 
remains unsure, especially in view of a number of studies 
that have found no such effect.38–40 In fact, it is well known 
that such increases can take place just by drinking equivalent 
amounts of water, ranging from 250 to 1000 mL.41–47 That 
normal coffee drinking is not associated with an effect on 
IOP has been shown also by a large cohort study.48 Further, 
it should be pointed out that coffee is not analogous to 
caffeine,49 the former being a complex mixture of compounds 
containing several other physiologically active compounds 
such as furfurals and acrolein.
Information about the effect of caffeine per se on IOP 
in patients with glaucoma/ocular hypertension is not yet 
available, except for one study where oral administration 
of caffeine was found to be ineffective in raising IOP.50 
  However, such studies are still lacking in glaucoma patients, 
who are known to have significant alterations in aqueous 
dynamics and IOP. The effect of a continued supply of caf-
feine to the aqueous humor also remains to be studied to 
determine whether there are any cumulative effects.
A study of the effects of direct topical application of caf-
feine on IOP in patients with glaucoma was thus desirable, 
especially in view of the many recent observations strongly 
suggesting that the compound has significant positive health 
effects such as the prevention of diseases such as Alzheimer’s 
and Parkinson’s-like diseases,51–58 and inhibition of the onset 
of diabetes.59,60 This study was therefore undertaken to deter-
mine the effect of caffeine on IOP in patients with glaucoma/
ocular hypertension, using direct topical administration of 
pure caffeine via eye drops, eliminating the possibility of 
indirect metabolic effects.
Contrary to expectations based on earlier observations of 
coffee drinking in relation to IOP in glaucoma patients, the   
results of this study indicate that direct application of caf-
feine to the eye does not exert any effect on IOP. This applied 
both in studies done within hours of caffeine instillation in 
the eye and when patients were treated consecutively 3 times 
a day for 6 days followed by another treatment on day 7. The 
authors’ studies suggest no reason for caution in the use of Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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caffeine in patients with open angle glaucoma, as similar 
small increases in IOP can be generated by water-drinking as 
seen in a provocative test for glaucoma. This is attributable   
to changes in body fluid osmotic dynamics.
Materials and methods
A 1% caffeine eye drop preparation was made by dissolv-
ing 100 mg of caffeine (Sigma Aldrich catalogue number 
58082; Sigma Aldrich, St Louis, MO) in 10 mL of sterile 
teardrop solution (0.3% hydroxyl-propyl methyl cellulose) 
(Sigma Aldrich) at room temperature. The solution was 
then divided, using sterile techniques, into 1 mL portions in 
eye drop vials and refrigerated. IOP was determined using 
a Perkins applanation tonometer (Clement Clarke Perkins 
MK-II; Clement Clarke International, Harlow, UK) after 
application of procaine/fluorescein eye drops (Smarth Life 
Sciences Nalagarh, Solan, Himachal Pradesh, India).
The five volunteers selected for the study were diagnosed 
to have primary open angle glaucoma/ocular hypertension. 
The age of the patients varied from 40 to 65 years. The 
group mean IOP was 23.6 ± 2.8 mmHg. They had not had 
any ocular surgical procedures such as cataract extraction or 
laser photocoagulation treatment for retinopathy.
Basal intraocular pressures were taken at 10.00 am and 
labeled “A.” Immediately following, the caffeine eye drop 
preparation was instilled (50 µL) and the eye closed for 
proper mixing of the drop in the conjunctival cul-de-sac. An 
IOP measurement was then taken at 10.30 am (labeled “B”). 
Additional eye drops were then instilled in the respective 
eyes at 2 and 8 pm and IOP measured again 30 minutes 
after each instillation, that is, at 2.30 (C) and 8.30 pm (D), 
respectively. Thus, the total number of IOP measurements 
on each eye was four, including the initial basal reading. 
Blood pressures were taken at the beginning and at the end 
of the investigation, with no substantial change revealed. 
  Subsequently, the patients were asked to instill the eye drops 
three times daily at the above times for 6 days and then 
return to the clinic on day 7. The above schedule of drop 
instillation and IOP measurements was then repeated. The 
patients were then withdrawn from the study and started on 
antiglaucoma medications.
Results
The initial mean IOP level in the volunteers prior to 
caffeine drop instillation was 23.6 ± 2.8 mmHg. The 
levels 30 minutes after each subsequent treatment 
were 23.2 ± 1.93, 22.2 ± 1.99, and 22.6 ± 2.31 mmHg, 
respectively. As summarized in Figure 1, no significant 
effect from the caffeine drops was noticeable. Repeated 
drop instillation did not show any enhancement of IOP. 
Blood pressure levels also remained unaffected. The results 
of the initial 1-day study were statistically analyzed and 
are summarized in Table 1.
To examine the possibility of any long-term effect of 
caffeine administration, the above study was extended by 
asking the patients to use the caffeine drops 3 times a day 
for 6 additional days, as per schedule used during the initial 
1-day study, and return to the clinical on day 7 for further 
pressure measurements. On their return, the patients did not 
report any unwanted effects except for a general feeling of 
well-being. Measurement of IOP and caffeine administration 
was repeated on return as above. The results of this second 
investigation were statistically analyzed and are summarized 
in Table 2 (see also Figure 2, a bar diagram for easier compre-
hension). “A” represents the basal readings obtained without 
any further treatment with the caffeine eye drops. “B,” “C,” 
and “D” represent the data after caffeine administration as 
described above for the 1-day investigation. Contrary to 
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Figure 1 The bars represent the intraocular pressure of patients given caffeine eye 
drops as described for Table 1 (the 1-day study).
Notes: The times indicated sequentially represent measurements A to D. The 
extended lines on the bar represent standard deviations.
Table 1 effect of caffeine eye drops on intraocular pressure: 
1-day treatment study
A B C D
Mean iOP 23.6 23.2 22.2 22.6
standard deviation 2.8 1.93 1.99 2.31
t with A reference 0.37 1.3 0.87
Variance (p)/A* 0.71 0.21 0.4
Notes: (A) represents the basal iOPs (mmhg). (B) represents the values soon after 
the first treatment. To look for a possible cumulative effect, eye drop instillation was 
repeated after 4 hours (C) and 6 hours (D) and iOP determined 30 minutes after 
each administration. The total number of eyes was ten, using the right as well the 
left eyes of five subjects. Contralateral difference was 1.4 ± 0.69 mmhg. *Variance 
(p) of the iOPs under B, C, and D with referece to the iOP under A, based on the 
corresponding t values indicated above.
Abbreviation: iOP, intraocular pressure.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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with loss of cognitive performance.57,58 Recent reports also 
suggest that caffeine decreases the risk of development of 
type 2 diabetes,59,60 loss of liver function and cirrhosis,61,62 
and development of certain cancers.63–68
Previous reports suggesting an association between 
  regular use of caffeine and development of hypertension have 
been significantly toned down in view of recent epidemio-
logical findings.69 The association between hypertension and 
coffee intake could not be established in a study based on at 
least 155,000 nurses.70 A Harvard study of 128,000 people 
concluded that coffee consumption is not associated with 
coronary heart disease unless it is used in combination with 
cigarette smoking and excessive use of alcohol. These and 
many other positive reports, including caffeine’s biochemical 
properties of scavenging reactive oxygen species, strongly 
suggest the desirability of further studies regarding its effect 
on the pathophysiology of ocular diseases. Based on earlier 
suggestions of possible transient increase in blood pressure 
caused by caffeine in persons who are not habitual users,4 it 
was speculated that the caffeine present in coffee might also 
increase IOP, as a hemodynamic effect. A transient increase 
of 1–2 mmHg pressure following coffee drinking has indeed 
been found to be the case in some reports34–36 but not in 
others.37–40 The pathophysiological significance of such a 
small change, if true, remains to be established.
Coffee is not analogous to caffeine.49 Therefore, attribut-
ing the effects of coffee drinking on IOP elevation solely to 
coffee’s caffeine content may be misleading, because coffee 
contains several other physiologically active substances 
derived from the coffee beans endogenously, as well as those 
produced during its processing by roasting and the preparation 
of the drink itself. Roasted coffee beans are known to contain 
several bioactive ingredients such as furfural and its deriva-
tives, formaldehyde, and acrolein,71,72 just to mention a few 
that are all known to be toxic to the eye.73 Their concentrations 
also differ. It is therefore difficult to exclude the possibility 
that variation in the levels of these constituents in different 
coffee brands and preparations might have been responsible 
for the differences in results reported on IOP in coffee-
drinking patients. This limitation applies even in studies 
where tea, with lower amounts of caffeine (∼3 mg), was used 
as a control. Its composition is very different to that of coffee 
beans. It was therefore necessary to investigate the effect of 
caffeine on IOP in glaucoma patients by topical application 
of the chemically pure compound. Additional studies were 
also considered important because several recent studies 
suggest that caffeine appears beneficial to ocular tissues by 
protecting them against OH• radical-induced oxidative stress.   
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Figure 2 The bars represent the intraocular pressure on patients given caffeine eye 
drops as described under Table 2, (the 1 week study).
Notes: The times indicated sequentially represent measurements A to D. The 
extended lines on the bar represent standard deviations.
Table 2 effect of caffeine eye drops on intraocular pressure: 
1-week study
Groups A B C D
Mean iOP 22.6 23.0 22.4 23.0
standard deviation 2.32 2.16 2.27 1.94
t with A reference 0.39 0.19 0.48
Variance (p)/A 0.69 0.85 0.68
Note: After 6 days of 3 times daily application, the procedure described in Table 1 
was repeated with identical times of drop instillation and iOP measurements. The 
total number of eyes remained at ten, using the right as well the left eyes of five 
subjects. Contralateral difference was 1.3 ± 0.99 mmhg.
expectations, no increase or decrease of IOP was noticed 
even in this study. The individual basal readings, as well as 
those determined 30 minutes after administering the drops, 
remained essentially unchanged. The reading in the group 
before administration of any drops was 22.6 ± 2.32 mmHg. 
This was similar to that obtained in the 1-day experiment, 
which was 23.6 ± 2.8.   Subsequent readings at the above time 
points were 23, 22.4, and 23 mmHg, respectively, indicating 
no change in IOP after caffeine drop treatment.
Discussion
Caffeine is widely present in various beverages and food 
items. Medically, it is frequently used as a CNS stimulant 
and for treating asthma and apnea, the latter primarily in 
preterm infants.4 The US Food and Drug Administration 
lists this compound as generally safe for human consump-
tion, the median lethal dose being high (10–15 g in a 
single dose), which is equivalent to 80–100 cups of coffee. 
Achieving lethality is difficult. Additionally, regular use of 
this compound, mostly from coffee or other common bever-
ages, has been reported to provide several very significant 
health benefits such as reduced incidence of Alzheimer’s 
and Parkinson’s diseases,51–56 senile dementia, and preven-
tion of neural degeneration in general which is associated Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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In addition, caffeine can support the tissues metabolically 
by inhibiting c-AMP phosphodiesterase and thereby main-
taining c-AMP levels.74–76 Caffeine’s effect in boosting body 
ergonomics and memory is now well accepted.
The observed ineffectiveness of caffeine in elevating 
IOP is not due to any lower doses than can be derived from 
drinking coffee. The amount used was much higher than that 
achievable by coffee drinking. The peak plasma level of caf-
feine following coffee drinking, 1 hour after consumption, 
varies from 3 to 12 mg/L.77 Being freely diffusible, this level 
will be similar in intraocular fluids including the aqueous 
humor. The initial amount of caffeine instilled in the eyes in 
these experiments was 0.5 mg present in 50 µL of the drop 
preparation. On closing the eye after instillation, most of it 
leaked out through the palpebral fissure and nasolacrimal 
pathway, so about 8–10 µL was retained in the conjuncti-
val sac. Hence, at maximum, a bolus of 0.1 mg of caffeine 
remains available to equilibrate with the aqueous, with the 
instant theoretical level of 0.5 mg/mL, (4.5 mM), taking the 
aqueous volume to be ∼0.2 mL. Topical instillation of such 
caffeine drops elevates the aqueous level significantly, as 
predicted above and as has been shown previously in experi-
ments with rats.78
In summary, therefore, studies with pure caffeine 
convincingly demonstrate that caffeine does not have any 
significant effect on IOP in patients with glaucoma/ocular 
hypertension, as is the case in humans without glaucoma/
ocular hypertension given oral doses of caffeine.50
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Barone JJ, Robert HR. Caffeine consumption. Food Chem Toxicol. 
1996;34:119–129.
2.  wiseGeek. How much caffeine is consumed by the average person? [Web 
page on the Internet.] Sparks, NV: wiseGeek; nd. Available from: http://
www.wisegeek.com/how-much-caffeine-is-consumed-by-the-average-
person.htm. Accessed September 13, 2011.
3.  Energy Fiend. Caffeine: consumption by country [web page on the 
Internet]. Energy Fiend; nd [updated August 18, 2011]. Available from: 
http://www.energyfiend.com/caffeine-what-the-world-drinks. Accessed 
September 13, 2011.
4.  Serafin WE. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, 
  Goodman Gillman A, editors. Goodman and Gillman’s   Pharmacological 
Basis of Therapeutics. 9th edition. New York: McGraw Hill; 1996: 
673–679.
5.  Arnaud MJ. The pharmacology of caffeine. Prog Drug Res. 1987;31: 
273–313.
6.  Wilson DF. Effect of caffeine on neuromuscular transmission in rats. 
Am J Physiol. 1973;225(4):862–865.
7.  Daly JW, Burns RF, Snyder SH. Adenosine receptor in the central nervous 
system; Relationship to the central actions of methylxanthines. Life Sci. 
1981;28(19):2083–2097. 
  8.  Dunwiddie TV. Interactions between the effects of adenosine and 
calcium on synaptic responses in rat hippocampus in vitro. J Physiol. 
1984;350:545–559.
  9.  Morgan MD, Vestal RE. Methylxanthine effects on caudate 
  dopamine release as measured by in vivo electrochemistry. Life Sci. 
1989;45:2025–2039.
  10.  Pedata F, Giovanelli L, De Samo P, Pepeu B. Effect of adenosine deriva-
tives and caffeine on acetylcholine release from the brain synaptosomes: 
Interaction with muscarinic autoregulatory mechanisms. J Neurochem. 
1986;46(5):1593–1598.
  11.  Solinas M, Ferre S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR. 
Caffeine induces dopamine and glutamate release in the shell of the 
nucleus accumbens. J Neurosci. 2002;22(15):6321–6324.
  12.  Degubareff T, Sleator W Jr. Effects of caffeine on t mammalian atrial 
muscle and its interaction with adenosine and calcium. J Pharmacol 
Exp Ther. 1965;148:202–214.
  13.  Blinks JO, Olson CB, Jewell BR, Braveny P. Influence of caffeine and 
other methyl xanthines in the mechanical properties of isolated mam-
malian heart muscle. Circ Res. 1972;30(4):367–392.
  14.  Dobemeyer JJ, Stein RA, Leier RA, Greenberg R, Schaal SF. The 
arrythmogenic effects of caffeine in human beings. N Engl J Med. 
1983;308(14):814–816.
  15.  Ogawa Y, Ebashi S. Ca-Releasing action of βγ-methylene adenos-
ine triphosphate on fragmented sarcoplasmic reticulum. J Biochem. 
1976;80(5):1149–1157.
  16.  Rousseau E, Ladine J, Liu QY, Meissner G. Activation of Ca2+ release 
channel of skeletal muscle sarcoplasmic reticulum by caffeine and 
related compounds. Arch Biochem Biophys. 1988;267(1):75–86.
  17.  Bhat MB, Zhao J, Zang W, et al. Caffeine-induced release of intra-
cellular Ca2+ from Chinese hamster ovary cells expressing skeletal 
muscle ryanodine receptor. Effects on full length carboxyl-terminal por-
tion of Ca2+ release channels. J Gen Physiol. 1997;110(6):749–762.
  18.  Coronado R, Morrissette J, Sukhareva M, Vaughan DM. Structure 
and function of ryanodine receptors. Am J Physiol. 1994;226(6 Pt 1): 
C1485–C1504.
  19.  Echeverri D, Montes FR, Cabrera M, Galan A, Prieto A. Caffeine’s 
vascular mechanisms of action. Int J Vasc Med. 2010;2010:834060.
  20.  Acheson KH, Zahorska-Mickiewicz B, Pittet P, Anantharaman K, 
Jequier E. Caffeine and coffee: their influence on metabolic rate and 
substrate utilization in normal weight and obese individuals. Am J Clin 
Nutr. 1980;33(5):989–997.
  21.  Bauer J, Maier K, Linderkamp O, Hentschel R. Effects of caffeine on 
oxygen consumption and metabolic rate in very low birth weight infants 
with idiopathic apnea. Pediatrics. 2001;107(4):660–663.
  22.  Belza A, Toubro S, Astrup A. The effect of caffeine, green tea and 
tyrosine on thermogenesis and energy intake. Eur J Clin Nutr. 
2009;63(1):57–64.
  23.  Yeo SE, Jentjens RL, Wallis GA, Jeukendrup AE. Caffeine increases 
exogenous carbohydrate oxidation during exercise. J Appl Physiol. 
2005;99(3):844–850.
  24.  Beavo JA, Rogers NL, Crofford OB, Hardman JG, Sutherland WW, 
Newman EV . Effect of xanthine derivatives on lipolysis and on adenos-
ine 3′,5′-monophosphate phosphodiesterase activity. Mol Pharmacol. 
1970;6(6):597–603.
  25.  Shi X, Dalal NS, Jain AC. Antioxidant behavior of caffeine: efficient 
scavenging of hydroxyl radicals. Food Chem Toxicol. 1991;29(1):1–6.
  26.  Stadler RH, Fay LB. Antioxidative reactions of caffeine: formation of 
8-oxocaffeine (1,3,7 trimethyl uric acid) in coffee subjected to oxidative 
stress. J Agric Food Chem. 1995;43:1332–1338.
  27.  Devasagayam TP, Kamat JP, Mohan H, Kesavan PC. Caffeine as an 
antioxidant: inhibition of lipid peroxidation induced by reactive oxy-
gen species. Biochim Biophys Acta. Bio membranes. 1996;1282(1): 
63–70.
  28.  Stadler RH, Richoz J, Turesky RJ, Welti DH, Fay LB.   Oxidation 
of  caffeine  and  related  methylxanthines  in  ascorbate  and 
  polyphenol-driven Fenton-type oxidations. Free Radic Res. 1996;24(3): 
225–240.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1628
Chandra et al
  29.  Varma SD, Kumar S, Richards RD. Light-induced damage to ocular 
lens cation pump: prevention by vitamin C. Proc Natl Acad Sci U S A. 
1979;76(7):3504–3506.
  30.  Chung WG, Cha YN. Oxidation of caffeine to theobromine and theo-
phylline is catalyzed primarily by flavin-containing monooxygenase 
in liver microsomes. Biochem Biophys Res Commun. 1997;235(3): 
685–688.
  31.  Dalmazio I, Santos LS, Lopes RP, Eberlin MN, Augusti R. Advanced 
oxidation of caffeine in water: On-line and real-time monitoring by 
electrospray ionization mass spectrometry. Environ Sci Technol. 
2005;39(16):5982–5988.
  32.  Telo JP, Vieira AJ. Mechanism of free radical oxidation of caffeine in 
aqueous solution. J Chem Soc Perkin Trans. 1997;2:1755–1757.
  33.  Varma SD, Kovtun S, Hegde K. Role of ultraviolet irradiation 
and oxidative stress in cataract formation: medical prevention by 
nutritional antioxidants and metabolic agonists. Eye Contact Lens. 
2011;37(4):233–245.
  34.  Higginbotham EJ, Kilimanjaro HA, Wilensky JT, Batenhorst RL, 
Hermann D. The effect of caffeine on intraocular pressure in glaucoma 
patients. Ophthalmology. 1989;96(5):624–626.
  35.  Avisar R, Avisa E, Weinberger D. Effect of coffee consumption on 
intraocular pressure. Ann Pharmacother. 2002;36(6):992–995.
  36.  Leydhecker W. Glaukom, ein Handbuch [Handbook of Glaucoma]. 
Berlin: Springer-Verlag; 1960.
  37.  Peczon JD, Grant WM. Sedatives, stimulants, and intraocular pressure 
in glaucoma. Arch Ophthalmol. 1964;72:178–188.
  38.  Chandrasekaran S, Rochtchina E, Mitchell P. Effect of caffeine on 
intraocular pressure: The Blue Mountains Eye Study. J Glaucoma. 
2005;14(6):504–507.
  39.  Jim and Looker [Internet pseudonyms]. Caffeine and ocular   pressure? 
MedKB.com [forum on the Internet]. MedKB; November 2003. 
  Available from: http://www.medkb.com/Uwe/Forum.aspx/glaucoma/97/
Caffiene-and-occular-pressure. Accessed September 13, 2011.
  40.  Wilensky JT. Glaucoma. Eye Facts [website on the Internet]. Chicago, 
IL: University of Illinois Department of Ophthalmology and Visual 
Sciences; November 10, 2010. Available from: http://www.uic.edu/
com/eye/LearningAboutVision/EyeFacts/Glaucoma.shtml. Accessed 
September 13, 2011.
  41.  Leydhecker W. The water-drinking test. British J Ophthalmol. 
1950;34(8):457–479.
  42.  Buckingham T, Young R. The rise and fall of intra-ocular pressure; 
the influence of physiological factors. Ophthalmic Physiol Opt. 
1986;6(1):95–99.
  43.  Drance SM. Studies with applanation water tests. Arch Ophthalmol. 
1963;69:39–43.
  44.  Moura  MA,  Rodrigues  LO, Waisberg Y,  De Almeida  HG, 
Silami-Garcia E. Effects of submaximal exercise with water ingestion 
on intraocular pressure in healthy human males. Braz J Med Biol Res. 
2002;35(1):121–125.
  45.  Armaly MF, Sayegh RE. Water-drinking test. II. The effect of 
age on tonometric and tonographic measures. Arch Ophthalmol. 
1970;83(2):176–181.
  46.  Alimuddin M. Normal intra-ocular pressure. Br J Ophthalmol. 1956;40(6): 
366–372.
  47.  Agarwal LP, Sharma CK. Two provocative tests for glaucoma. Br J 
Ophthalmol. 1955;37(6):330–335.
  48.  Kang JH, Willet WC, Rosner BA, Hankinson SE, Pasquale LR. Caffeine 
consumption and the risk of primary open-angle glaucoma: a prospective 
cohort study. Invest Ophthalmol Vis Sci. 2008;49(5):1924–1931.
  49.  Illy E. The complexity of coffee. Scientific American. 2002;286(6): 
86–91.
  50.  Adams BA, Brubaker RF. Caffeine has no clinically significant effect 
on aqueous humor flow in the normal human eye. Ophthalmology. 
1990;97(8):1030–1031.
  51.  Maia L, de Mendonça A. Does caffeine intake protect from Alzheimer’s 
disease? Eur J Neurol. 2002;9(4):377–382.
  52.  Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer’s 
Disease: a prospective analysis from the Canadian Study of Health and 
Aging. Am J Epidemiol. 2002;156(5):445–453.
  53.  Institute of Holistic Nutrition. Caffeine anyone? Available at:http://
www.sciencedaily.com/releases/2009/01/090114200005.htm.
  54.  Ritchie K, Carriere I, de Mendonca A, et al. The neuroprotective effects 
of caffeine: a prospective population study (the Three City Study). 
Neurology. 2007;69(6):536–545.
  55.  Ross GW, Abbott RD, Petrovich H, et al. Association of   coffee 
and caffeine intake with the risk of Parkinson disease. JAMA. 
2000;283(20):2674–2679.
  56.  Benedetti MD, Bower JH, Maraganore DM, et al. Smoking, alcohol, 
and coffee consumption preceding Parkinson’s disease. Neurology. 
2000;55(9):1350–1358.
  57.  Jarvis MJ. Does caffeine intake enhance absolute levels of cognitive 
performance? Psychopharmacology. 2005;110(1–2):45–52.
  58.  Johnson-Kozlow M, Kritz-Silverstein D, Barrett-Connor E, Morton D. 
Coffee consumption and cognitive function among older adults. Am J 
Epidemiol. 2002;156(9):842–850.
  59.  Salazar-Martinez E, Willett WC, Ascherio A, et al. Coffee con-
sumption and risk for type 2 diabetes mellitus. Ann Intern Med. 
2004;140(1):1–8.
  60.  Huxley R, Lee CM, Barzi F, et al. Coffee, decaffeinated   coffee, 
and tea consumption in relation to incident type 2 diabetes 
  mellitus: a systematic review with meta-analysis. Arch Intern Med. 
2009;169(22):2053–2063.
  61.  Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and 
transaminase enzymes. Arch Intern Med. 2006;166(11):1190–1195.
  62.  Cadden IS, Partovi N, Yoshida EM. Review article: possible beneficial 
effects of coffee on liver disease and function. Aliment Pharmacol. 
2007;26(1):1–8.
  63.  Inoue M, Yoshimi I, Sobue T, Tsugane S. JPHC Study Group. 
  Influence of coffee drinking on subsequent risk of hepatocellular 
  carcinoma: a prospective study in Japan. J Natl Cancer Inst. 2005;97(4): 
293–300.
  64.  Rodriguez T, Altieri A, Chatenoud L, et al. Risk factors for oral 
and pharyngeal cancer in young adults. Oral Oncol. 2004;40(2): 
207–213.
  65.  Tavani A, Bertuzzi M, Talamini R, et al. Coffee and tea intake 
and risk of oral, pharyngeal and esophageal cancer. Oral Oncol. 
2003;39(7):695–700.
  66.  Song YJ, Kristal AR, Wicklund KG, Cushing-Haugen KL, Rossing MA. 
Coffee, tea, colas, and risk of epithelial ovarian cancer. Cancer Epide-
miol Biomarkers Prev. 2008;17(3):712–716.
  67.  Ganmaa D, Willett WC, Li TY, et al. Coffee, tea, caffeine and risk of breast 
cancer: a 22-year follow-up. Int J Cancer. 2008;122(9):2071–2076.
  68.  Flatow J, Wilson K. can coffee lower the risk of prostate cancer [Tran-
script.] National Public Radio. December 11, 2009. Available at: http://
www.npr.org/templates/story/story.php?storyId=121343438. Accessed 
September 21, 2011.
  69.  Cromie W. Coffee gets cleared of blood pressure risk. Harvard Gazette. 
Nov 2005;10:2006. Available at: http://www.news.harvard.edu/
gazette/2005/11.10/06-coffee.html.
  70.  Lopez-Garcia E, van Dam RM, Willett WC, et al. Coffee consumption 
and coronary heart disease in men and women: a prospective cohort 
study. Circulation. 2006;113(17):2045–2053.
  71.  Rizzi GP. Formation of sulfur-containing volatiles under coffee   roasting. 
In: Parliament TH, Ho CT, Schieberle. Caffeinated Beverages: Health 
Benefits, Physiological Effects, and Chemistry. ACS Symposium Series, 
Vol 754. Washington, DC: American Chemical Society; 2000:210–215.
  72.  Quarta B, Anese M. Furfurals removal from roasted coffee powder by 
vacuum treatment. Food Chem. 2011;130:610–614.
  73.  Grant WM. Toxicology of the Eye. 2nd ed. Springfield Illinois: Charles 
C Thomas; 1974:590, 502.
  74.  Varma SD, Hegde KR. Prevention of oxidative damage to lens by 
  caffeine. J Ocul Pharmacol Ther. 2010;26(1):73–77.Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1629
effect of caffeine on iOP in glaucoma
  75.  Varma SD, Hegde KR. Kynurenine-induced photo oxidative   damage 
to lens in vitro: protective effect of caffeine. Mol Cell Biochem. 
2010;340(1–2):49–54.
  76.  Wang L, Lu L. Pathway-specific effect of caffeine on protection against 
UV irradiation-induced apoptosis in corneal epithelial cells. Invest 
Ophthalmol Vis Sci. 2007;48(2):652–660.
  77.  Baselt R. Disposition of Toxic Drugs and Chemicals in man. (9th ed.) 
Seal Beach, CA: Biomedical Publications; 2011.
  78.  Varma SD, Kovtun S, Hegde K. Effectiveness of topical caffeine 
in cataract prevention: studies with galactose cataract. Mol Vis. 
2010;16:2626–2633.